BioRap, HaptoGuard to Develop Treatment Technologies

BioRap Technologies announced that it has expanded its license and research agreement with HaptoGuard, an American biopharmaceutical company focused on the development and commercialization of anti-inflammatory therapeutics for large, underserved populations. The agreement will allow HaptoGuard to further develop diagnostic and therapeutic products for the management and treatment of diabetes-related complications.

()a href="http://www.genengnews.com/news/bnitem.aspx?name=535271XSL_NEWSML_TO_NEWSML_WEB.xml" target="_blank">Genetic Engineering News